Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab in unresectable malignant peripheral nerve sheath tumor
2015-004747-39Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- Nov 2015
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in malignant peripheral nerve sheath tumor (MPNST), sponsored by Oslo University Hospital. Primary endpoint: Clinical response at 18 weeks. Started Nov 2015; status: terminated.
02
Drugs
03
Conditions
malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on 2015-004747-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004747-39.